aod9604 clinical trials weight loss results AOD 9604 vs. Semaglutide: A Comparison Exploring AOD 9604: Before and
Description
They are not intended for human or animal use, bodily introduction, consumption, administration, therapeutic use, diagnostic use, cosmetic use, dietary supplement use, or any form of clinical application
It aids in breaking down fat, removing heavy metals from the body, and digestion
GLP-1 agonists commonly cause nausea, vomiting, and gastrointestinal distress, particularly during dose escalation
Increase to 500 mcg on the second or third injection if tolerated
MOTS-c is not FDA-approved and long-term human safety data does not exist
